In line Q4 sales; lower-than-expected 2024 guidance
08/02/24 -"Ipsen’s Q4 sales met expectations. Healthy growth in Oncology and a positive contribution from Rare Disease portfolio were somewhat offset by the decline in Neuroscience. Meanwhile, markets were ..."
Pages
52
Language
English
Published on
08/02/24
You may also be interested by these reports :
26/07/24
The Q2 results came in ahead of expectations, driven by a strong showing across most target areas. As we had indicated the possibility earlier, the ...
26/07/24
The Q2 results beat the market’s expectations, driven by the robust momentum for Dupixent, the healthy trajectory for new launches, and strong growth ...
26/07/24
The outlook has improved, though challenges remain. The company initially lost credibility after announcing a weak 2024 outlook back in the autumn of ...
25/07/24
The Q2 results came in ahead of expectations, with healthy growth witnessed across the targeted areas. Consequently, the management revised its ...